Emixustat

Emixustat is an orally active RPE65 inhibitor with an IC50 value of 4.4 nM. Emixustat is also a visual cycle modulator, capable of regulating visual cycle activity by inhibiting retinol isomerization, and holds potential for studying vision disorders such as age-related macular degeneration (AMD) [1][2][3][4].

Product Specifications

CAS Number

[1141777-14-1]

Product Name Alternative

ACU-4429

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

RPE65

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/Emixustat.html

Purity

98.74

Solubility

DMSO : ≥ 43 mg/mL|Ethanol : 100 mg/mL (ultrasonic)

Smiles

O[C@H](CCN)C1=CC(OCC2CCCCC2)=CC=C1

Molecular Formula

C16H25NO2

Molecular Weight

263.38

Precautions

H302, H315, H319

References & Citations

[1]Bavik C, et al. Visual Cycle Modulation as an Approach toward Preservation of Retinal Integrity. PLoS One. 2015 May 13;10 (5) :e0124940.|[2]Kiser PD, et al. Catalytic mechanism of a retinoid isomerase essential for vertebrate vision. Nat Chem Biol. 2015 Jun;11 (6) :409-15.|[3]Kubota R, et al. Emixustat Reduces Metabolic Demand of Dark Activity in the Retina. Invest Ophthalmol Vis Sci. 2019 Nov 1;60 (14) :4924-4930.|[4]Bavik C, et al. Visual Cycle Modulation as an Approach toward Preservation of Retinal Integrity. PLoS One. 2015 May 13;10 (5) :e0124940.